153 related articles for article (PubMed ID: 17876040)
1. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
[TBL] [Abstract][Full Text] [Related]
2. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
Wickström M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknäs M; Vogel LK; Lewensohn R; Larsson R; Gullbo J
Biochem Pharmacol; 2010 May; 79(9):1281-90. PubMed ID: 20067771
[TBL] [Abstract][Full Text] [Related]
3. The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
Wickström M; Haglund C; Lindman H; Nygren P; Larsson R; Gullbo J
Invest New Drugs; 2008 Jun; 26(3):195-204. PubMed ID: 17922077
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
Gullbo J; Lindhagen E; Bashir-Hassan S; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; De La Torre M; Luthman K; Larsson R
Invest New Drugs; 2004 Nov; 22(4):411-20. PubMed ID: 15292711
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
[TBL] [Abstract][Full Text] [Related]
7. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
J Drug Target; 2003 Jul; 11(6):355-63. PubMed ID: 14668056
[TBL] [Abstract][Full Text] [Related]
8. Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma.
Taylor JS; Yavuz B; Zeki J; Wood L; Ikegaki N; Coburn J; Harrington K; Shimada H; Kaplan DL; Chiu B
Surgery; 2020 Jun; 167(6):969-977. PubMed ID: 32122657
[TBL] [Abstract][Full Text] [Related]
9. The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.
Mendonça-Torres MC; Roberts SS
Cancer Biol Ther; 2013 Apr; 14(4):319-26. PubMed ID: 23358477
[TBL] [Abstract][Full Text] [Related]
10. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
[TBL] [Abstract][Full Text] [Related]
11. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
Corbett R; Pinkerton R; Pritchard J; Meller S; Lewis I; Kingston J; McElwain T
Eur J Cancer; 1992; 28A(8-9):1324-8. PubMed ID: 1515243
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
14. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.
Lange B; Schroeder U; Huebener N; Jikai J; Wenkel J; Strandsby A; Wrasidlo W; Gaedicke G; Lode HN
Cancer Lett; 2003 Jul; 197(1-2):225-30. PubMed ID: 12880986
[TBL] [Abstract][Full Text] [Related]
15. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
16. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
Keshelava N; Seeger RC; Reynolds CP
Eur J Cancer; 1997 Oct; 33(12):2002-6. PubMed ID: 9516842
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
19. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
